Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
214.20B
Market cap214.20B
Price-Earnings ratio
11.41
Price-Earnings ratio11.41
Dividend yield
3.76%
Dividend yield3.76%
Average volume
11.15M
Average volume11.15M
High today
$86.57
High today$86.57
Low today
$85.24
Low today$85.24
Open price
$85.95
Open price$85.95
Volume
9.21M
Volume9.21M
52 Week high
$105.07
52 Week high$105.07
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

With a market cap of 214.2B, Merck(MRK) trades at $86.57. The stock has a price-to-earnings ratio of 11.41 and currently yields dividends of 3.8%.

As of 2025-11-10, Merck(MRK) stock has fluctuated between $85.24 and $86.57. The current price stands at $86.57, placing the stock +1.6% above today's low and 0.0% off the high.

The Merck(MRK)'s current trading volume is 9.21M, compared to an average daily volume of 11.15M.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.

MRK News

TipRanks 11h
Merck announces first presentation of results from Phase 3 CORALreef HeFH

Merck (MRK), known as MSD outside of the United States and Canada, announced the first presentation of results from the Phase 3 CORALreef HeFH trial demonstrati...

Nasdaq 22h
Merck's Enlicitide Shows Promising Results In Phase 3 CORALreef Lipids Trial

(RTTNews) - Merck & Co Inc. (MRK) has unveiled the first results from its pivotal Phase 3 CORALreef Lipids trial, highlighting the efficacy of enlicitide decano...

Merck's Enlicitide Shows Promising Results In Phase 3 CORALreef Lipids Trial
Investor's Business Daily 2d
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

Merck (MRK) said Saturday its new pill — a potential rival to injections from Regeneron Pharmaceuticals (REGN) and Amgen (AMGN) — lowered stubbornly high choles...

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

Analyst ratings

59%

of 27 ratings
Buy
59.3%
Hold
40.7%
Sell
0%

More MRK News

Simply Wall St 2d
Assessing Merck’s Valuation as Shares Regain Momentum After Recent Volatility

Merck (MRK) shares are starting the week with a modest uptick, trading higher after recent volatility. Some investors are keeping an eye on the company’s longer...

Assessing Merck’s Valuation as Shares Regain Momentum After Recent Volatility
TipRanks 2d
Insider Moves: JPMorgan, Adobe, Eli Lilly, McDonald’s, Merck

Insiders have been trading these 5 stocks: ((JPM)), ((ADBE)), ((LLY)), ((MCD)) and ((MRK)). Here is a breakdown of their recent trades and their value. Meet Yo...

Simply Wall St 3d
Examining Merck’s Recent Drop and Oncology Partnership for Clues on Real Value in 2025

Wondering if Merck is trading below its true worth, or if the market is missing something? You are not alone, and digging deeper can reveal some surprising valu...

Examining Merck’s Recent Drop and Oncology Partnership for Clues on Real Value in 2025
Simply Wall St 5d
Blackstone Funding Deal Might Change the Case For Investing In Merck

Merck recently announced an agreement to receive US$700 million in funding from Blackstone Life Sciences to advance the development of sacituzumab tirumotecan,...

Blackstone Funding Deal Might Change the Case For Investing In Merck
TipRanks 5d
Top Merck Executive Cashes In on Stock Sale

New insider activity at Merck & Company ( (MRK) ) has taken place on November 4, 2025. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

The Motley Fool 6d
Why Merck Is Sinking This Week

Investors were unimpressed with Merck's Q3 financial results. The stock for pharmaceutical giant Merck (MRK +1.28%) was trading down more than 3% Monday mornin...

Why Merck Is Sinking This Week
Seeking Alpha 6d
Merck to receive $700M from Blackstone to develop cancer therapy

Merck (MRK) on Tuesday announced an agreement under which funds managed by Blackstone (BX) Life Sciences will provide the New Jersey-based pharma giant with $70...

Merck to receive $700M from Blackstone to develop cancer therapy

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.